Key result
Multimodal imaging with TTE, CMR, and CCT guides tailored risk stratification and management in HCM.
Why the study?
Hypertrophic cardiomyopathy is a genetic cardiac disorder associated with significant morbidity and mortality, requiring comprehensive multimodal imaging for diagnosis, risk stratification, and management.
Multimodal imaging is essential for the comprehensive evaluation, risk stratification, and tailored management of patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Supports multimodal imaging in HCM; leaves open prospective validation before practice change.
Hypertrophic cardiomyopathy (HCM) is a genetic cardiac disorder associated with significant morbidity and mortality. This review highlights the essential role of multimodal imaging-transthoracic echocardiography (TTE), cardiac magnetic resonance (CMR), and cardiac computed tomography (CCT)-in the diagnosis, risk stratification, and management of HCM. TTE remains the first-line tool, while advanced techniques like CMR and CCT offer enhanced accuracy in tissue characterization, fibrosis detection, and procedural planning. By integrating these imaging modalities, clinicians can adopt a precision medicine approach, enabling tailored treatment strategies that address individual patient needs. This comprehensive use of imaging not only enhances clinical decision-making but also holds the potential to improve long-term outcomes for patients with HCM.
No takes yet. Share an insight, caveat, or question.
Karamarkou et al. (2025) conducted a review in Hypertrophic cardiomyopathy (HCM). Multimodal imaging (TTE, CMR, CCT) was evaluated. Multimodal imaging, including TTE, CMR, and CCT, plays an essential role in the diagnosis, risk stratification, and management of hypertrophic cardiomyopathy to enable tailored treatment strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: